Pfizer Inc (PFE.N) has not decided how it might divest its nutrition or animal health businesses, the drugmaker's chief financial officer said on Wednesday. Pfizer in July announced it was exploring options, including spin-off or sale, of the two businesses. Their combined value could reach about $25 billion to $32 billion, according to Credit Suisse analyst Catherine Arnold. A Bloomberg News report on Tuesday, citing anonymous sources, said that Pfizer was delaying a sale of the nutrition business to explore whether a tax-free spin-off was a better option. Asked about the report, Pfizer CFO Frank D'Amelio told an investor conference that no decision had been reached. "We haven't reached a conclusion on any structure," D'Amelio said at the Morgan Stanley Global Healthcare Conference in New York.
Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. Shares of PFE fell by 0.76% or $-0.14/share to $18.19. In the past year, the shares have traded as low as $16.25 and as high as $21.45. On average, 51751600 shares of PFE exchange hands on a given day and today's volume is recorded at 16064442.
Source
